Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.18
Nov 16 • 3:59 PM ET Dollar change+0.01 Percentage change(0.85%)
Aftermarket Close
1.18
Aftermarket • 5:00 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
173.89M
Enterprise Value
43.73M
Income
-
Sales
-
Book/sh
1.11
Cash/sh
0.89
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
65
IPO
Nov 08, 2017
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.06
P/C
1.33
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
7.26
Current Ratio
7.26
Debt/Eq
0.01
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-
EPS next Y
-0.34
EPS next Q
-0.05
EPS this Y
68.79%
EPS next Y
-46.46%
EPS next 5Y
17.74%
EPS past 3/5Y
-2.98% 11.77%
Sales past 3/5Y
- -
EPS Y/Y TTM
-40.62%
Sales Y/Y TTM
-
EPS Q/Q
92.08%
Sales Q/Q
-100.00%
Insider Own
14.75%
Insider Trans
0.00%
Inst Own
62.11%
Inst Trans
41.68%
ROA
-
ROE
-
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-19.55%
SMA50
-29.53%
SMA200
-28.81%
Trades
Shs Outstand
147.37M
Shs Float
125.63M
52W High
2.95 -59.99%
52W Low
0.80 47.80%
Volatility
10.78% 10.42%
ATR (14)
0.14
RSI (14)
31.96
Beta
2.45
Rel Volume
1.27
Avg Volume
814.73K
Volume
1,037,323
Perf Week
-9.92%
Perf Month
-10.61%
Perf Quarter
-45.87%
Perf Half Y
-52.80%
Perf YTD
16.83%
Perf Year
-12.59%
Perf 3Y
-18.62%
Perf 5Y
-75.72%
Perf 10Y
-
Prev Close
1.17
Price
1.18
Change %
0.85%
Consensus
Strong Buy
Avg. Price Target
$8.42
Implied Upside
+613.6%
Analysts13incl. previous ratings
Rating Distribution8 Buy · 4 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 14, 2026Initiated
NNeedham
Buy$8+578.0%
May 13, 2026Upgrade
RJF logoRRaymond James
Outperform → Strong Buy$9+662.7%
Apr 24, 2026Resumed
OPY logoOOppenheimer
Outperform$7 → $5+323.7%
Dec 03, 2025Downgrade
LLeerink Partners
Outperform → Market Perform$2+69.5%
Sep 02, 2025Resumed
HH.C. Wainwright
Buy$6+408.5%
May 29, 2025Downgrade
RJF logoRRaymond James
Strong Buy → Outperform$2+69.5%
Apr 29, 2025Initiated
CCantor Fitzgerald
Overweight$10+747.5%
Apr 05, 2023Upgrade
GGuggenheim
Neutral → Buy$8+578.0%
Feb 28, 2022Downgrade
GGuggenheim
Buy → Neutral
Oct 28, 2021Upgrade
RJF logoRRaymond James
Outperform → Strong Buy$10 → $14+1,086.4%
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
Co-FounderProf. Renfeng Guo M.D.
Chief Financial OfficerDr. Thomas Taapken Ph.D.
Senior VP and Global Head of Regulatory Affairs & ComplianceMs. Derval O'Carroll
Head of Investor Relations & VPMr. Jan Medina CFA
VPDr. Maria Habel PH.D.